The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Cardiff Oncology Inc (NASDAQ: CRDF) closed at $3.14 down -4.56% from its previous closing price of $3.29. In other words, the price has decreased by -$4.56 from its previous closing price. On the day, 0.84 million shares were traded. CRDF stock price reached its highest trading level at $3.22 during the session, while it also had its lowest trading level at $3.08.
Ratios:
For a deeper understanding of Cardiff Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.08 and its Current Ratio is at 7.08. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.Robert W. Baird initiated its Outperform rating on December 08, 2021, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 219564176 and an Enterprise Value of 118663280. For the stock, the TTM Price-to-Sale (P/S) ratio is 307.18 while its Price-to-Book (P/B) ratio in mrq is 2.52. Its current Enterprise Value per Revenue stands at 173.738 whereas that against EBITDA is -2.459.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.72, which has changed by -0.41527003 over the last 52 weeks, in comparison to a change of 0.077997446 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $6.38, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is -20.92%, while the 200-Day Moving Average is calculated to be 1.54%.
Shares Statistics:
For the past three months, CRDF has traded an average of 1.10M shares per day and 1183750 over the past ten days. A total of 66.52M shares are outstanding, with a floating share count of 59.79M. Insiders hold about 10.13% of the company’s shares, while institutions hold 34.43% stake in the company. Shares short for CRDF as of 1741910400 were 13341326 with a Short Ratio of 12.14, compared to 1739491200 on 10840447. Therefore, it implies a Short% of Shares Outstanding of 13341326 and a Short% of Float of 20.45.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
